Treatment needs to be individualized and may require the use of rational combinations (e.g., immunotherapy plus conventional therapies targeting RAS downstream cascade or cell cycle inhibitors) for a durable therapy response in KRAS+ NSCLC [57]. Here, KRAS is linked to non-small cell lung carcinoma.